Glenmark gains on receiving USFDA for Aspirin capsules

Shares of Glenmark were trading in green in early trade session as Glenmark Pharmaceuticals’ subsidiary, Glenmark Pharmaceuticals Inc, USA has been granted final approval by the USFDA for Aspirin and Extended‐Release Dipyridamole Capsules.

Aspirin and Extended‐Release Dipyridamole Capsules, 25 mg/200 mg is a generic version of Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The IQVIA sales data for the 12 month period ending March 2019 states that the Aggrenox Capsules, 25 mg/200 mg market achieved annual sales of approximately US$165.6 million.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

On Monday, the shares of Glenmark opened at Rs. 562 against Friday’s close of Rs. 559.05. At 9:55 hours, the stock was trading at Rs. 560.80 per share, 0.31 per cent higher than its previous close. It reached an intraday high of Rs 564.75 and an intraday low of Rs. 557.70 per share on the BSE. The 52-week high stood at Rs. 711.55 and 52-week low was at Rs. 483.60 per share on the BSE.